Autologous Cytokine-Induced Killer (CIK) Cell Therapy in Clinical Trial Phase I is Safe in Patients with Primary Hepatocellular Carcinoma

This study evaluates the safety and efficacy of autologous Cytokine-Induced Killer (CIK) cell therapy in patients with primary hepatocellular carcinoma (HCC). CIK cells, a heterogeneous population of immune cells derived from Peripheral Blood Mononuclear Cells (PBMCs), are expanded ex vivo using interferon-gamma (IFN-γ), interleukin-2 (IL-2), and anti-CD3 antibodies. The therapy was assessed for its impact on immune cell subsets, tumor progression, and patient safety.

🔍 Key Findings of the Paper

1. Background & Rationale

• HCC is highly lethal, with limited treatment options such as surgery, chemotherapy, and radiotherapy.
• HCC patients have compromised immune function, making them susceptible to tumor progression and recurrence.
• CIK cells are a promising adoptive immunotherapy, possessing both T cell (CD3+) and Natural Killer (NK) cell (CD56+) markers, which enable them to attack tumor cells via MHC-independent mechanisms.

2. Mechanisms of CIK Cell Therapy

✅ Expansion of Cytotoxic Effector Cells

• After two weeks of ex vivo expansion, the following immune cell subsets significantly increased:
  • CD3+CD8+ T cells: Increased from 33.5% to 36.6% (P<0.05).
  • CD3+CD56+ NKT cells: Increased from 7.7% to 18.9% (P<0.01).
  • CD25+ Activated T cells: Increased from 12.3% to 16.4% (P<0.05).
• NK cell levels remained stable, while CD3+CD4+ helper T cells showed no significant change.

✅ Dendritic Cell (DC) Activation and Immune Modulation

• DC1 and DC2 subsets increased after CIK therapy:
  • DC1 (antigen-presenting dendritic cells) increased from 0.59% to 0.85% (P<0.01).
  • DC2 (immune-regulating dendritic cells) increased from 0.26% to 0.43% (P<0.01).
• CIK therapy enhances anti-tumor immune responses by increasing T cell activation, antigen presentation, and cytokine secretion (IL-12, IFN-α, TNF-α).

✅ Reduction in HBV Viral Load & Tumor Progression

• HCC patients had chronic hepatitis B virus (HBV) infections.
• HBV DNA levels decreased significantly after CIK therapy:
  • Baseline: 1.85 × 10⁶ copies/mL
  • 1 month: 8.75 × 10⁵ copies/mL
  • 3 months: 1.41 × 10⁵ copies/mL
• Alpha-fetoprotein (AFP), a tumor marker, decreased in several patients.
• Tumor growth slowed in all patients, with tumor shrinkage observed in three patients.

✅ Safety and Tolerability

• No major adverse effects were reported.
• Some patients experienced mild fever (~37.5-40°C) after infusion, which resolved without intervention.
• No significant liver or kidney toxicity was observed.

🩺 Clinical Implications

1. Potential for HCC Immunotherapy

• CIK therapy improves immune surveillance against tumors, making it a promising complementary treatment for HCC patients.
• The therapy boosts T cell cytotoxicity, enhances dendritic cell activation, and lowers HBV viral load, potentially improving tumor control and long-term survival.

2. Applications in Other Cancers & Chronic Viral Infections

• CIK therapy’s ability to increase cytotoxic T cells and dendritic cell function suggests its applicability in other solid tumors and chronic viral infections (e.g., hepatitis C, HPV-related cancers).

🔗 Connection to Cell Signal Shot™

The Cell Signal Shot™ by NovaStem aligns with this study in PBMC-based immune modulation and regenerative applications.

1. Common Features

✔ PBMCs as the Key Regenerative Component

• Both Cell Signal Shot™ and this study utilize PBMC-derived immune cells to enhance immune function and tissue repair.

✔ Paracrine Signaling for Immune Enhancement

• Both therapies involve PBMC-derived cytokines and growth factors (e.g., IL-2, IFN-γ, VEGF) to promote tissue regeneration and immune function.

✔ Anti-Inflammatory and Tumor Control Effects

• Both approaches emphasize immune activation while suppressing chronic inflammation, which is critical for tissue healing and cancer control.

2. Differences & Potential Advancements

• CIK therapy uses expanded cytotoxic T and NK cells, while Cell Signal Shot™ focuses on PBMC-derived secretomes for tissue repair.
• Future studies could explore combining PBMC secretome therapy with CIK-like immune activation to create a hybrid regenerative-immunotherapy approach.

📌 Final Assessment

This study provides strong evidence that PBMC-based immune cell therapy can enhance anti-tumor immunity and improve immune function, aligning well with Cell Signal Shot™'s regenerative and immune-modulating capabilities.